In This Article

The short answer: The Omega-3 Index measures EPA and DHA as a percentage of total red blood cell fatty acids. An index below 4% is associated with significantly elevated cardiovascular mortality risk. Above 8% is considered cardioprotective. Most adults in Western countries sit between 4-6%, which is suboptimal. Getting to 8% or above requires either regular fatty fish consumption (3-4 servings per week) or targeted supplementation, because the omega-3 precursor from plant foods (ALA) converts to EPA and DHA at under 10% efficiency.

Read key takeaways →

What the Omega-3 Index actually measures

The Omega-3 Index is not a serum omega-3 level, which fluctuates with recent meals. It is the percentage of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in red blood cell membranes. Because red blood cells live for about 120 days, the index reflects your omega-3 status over the past 3-4 months, similar to HbA1c for blood sugar. It is a stable, reliable reflection of your tissue omega-3 status, not a snapshot of your last fish oil capsule.

EPA and DHA are the biologically active omega-3 fatty acids. They are structurally incorporated into cell membranes, where they influence membrane fluidity, receptor function, and cell signaling. They are also the precursors to resolvins and protectins: specialized pro-resolving lipid mediators that actively resolve inflammation (as opposed to merely suppressing it). Harris and Von Schacky (2004, Preventive Medicine) proposed the Omega-3 Index as a cardiovascular risk factor after analysis of the DART trial and Kuopio Ischemic Heart Disease Study data. The index is now available as a direct-to-consumer blood test.

Omega-3 Index Risk Zones

Below 4%

High cardiovascular risk zone. Associated with elevated sudden cardiac death risk. Most Americans and northern Europeans fall here without active supplementation.

4-8%

Intermediate zone. Risk is reduced relative to below 4% but cardioprotective benefit is not fully realized. Most people who take fish oil sporadically or eat fish occasionally land here.

Above 8%

Cardioprotective zone. Associated with the lowest cardiovascular event rates. Requires either very frequent fatty fish consumption or consistent, adequate supplementation.

The cardiovascular evidence

The Omega-3 Index below 4% versus above 8% comparison is associated with a 10-fold difference in risk for sudden cardiac death in the pooled cohort data from Harris and Von Schacky. That is a striking number. The mechanism involves anti-arrhythmic effects of EPA and DHA on cardiac ion channels (reduced ventricular fibrillation susceptibility) alongside anti-inflammatory and plaque-stabilizing effects.

The epidemiological evidence is robust. The JELIS trial (Japan, 2007, Lancet) enrolled over 18,000 patients with hypercholesterolemia and found that EPA supplementation at 1.8g/day reduced major coronary events by 19% in the secondary prevention group over 5 years. The REDUCE-IT trial (2018, NEJM) found that 4g/day of high-purity EPA (icosapent ethyl) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides. The REDUCE-IT result was so large it created controversy, in part because the control arm used mineral oil rather than inert placebo.

The Clinical Trial Nuance

  • →REDUCE-IT (2018, NEJM): Used 4g/day icosapent ethyl (EPA only, prescription). 25% reduction in MACE in statin-treated patients with elevated triglycerides. Effect may reflect triglyceride reduction, anti-inflammatory action, or both.
  • →STRENGTH trial (2020, JAMA): Used 4g/day EPA+DHA combination. No significant reduction in MACE. Raised questions about whether EPA alone versus EPA+DHA matters for clinical outcomes.
  • →VITAL trial (2019, NEJM): Used 1g/day EPA+DHA in a general population. No primary MACE reduction, but 28% reduction in fatal heart attacks in the subgroup analysis. Dose may have been insufficient for population-level benefit.
  • →Practical interpretation: The evidence most clearly supports high-dose EPA for people with elevated triglycerides and established cardiovascular disease. For primary prevention, optimizing the Omega-3 Index to above 8% is the most evidence-based target.

Omega-3s, inflammation, and recovery

Beyond cardiovascular risk, EPA and DHA have direct effects on the inflammatory resolution process, relevant for athletic recovery, metabolic health, and cognitive function. The pro-resolving mediators derived from EPA and DHA (resolvins E1 and E2, protectins D1, maresins) do not merely suppress inflammation. They actively resolve it: clearing cellular debris, reducing neutrophil infiltration, and restoring tissue homeostasis.

Calder (University of Southampton) has produced extensive research on the immunomodulatory effects of EPA and DHA. In training contexts, high omega-3 status is associated with reduced post-exercise inflammation, improved muscle protein synthesis (Smith et al., 2011, American Journal of Clinical Nutrition showed a 50% increase in MPS rate with 4g/day EPA+DHA over 8 weeks in older adults), and lower delayed onset muscle soreness from eccentric exercise.

What High Omega-3 Status Supports Beyond the Heart

  • →Muscle protein synthesis: EPA and DHA sensitize the mTOR pathway to leucine. Smith et al. (2011) showed 50% higher MPS rate with 4g/day supplementation over 8 weeks in older adults.
  • →Brain health and cognition: DHA is the dominant structural fatty acid in the brain, comprising 30-40% of total brain fatty acid content. Low DHA status is associated with faster cognitive decline and lower BDNF levels.
  • →HRV and autonomic function: EPA and DHA improve vagal tone and heart rate variability through their effects on ion channel function. Higher omega-3 index is associated with higher resting HRV in observational data.
  • →Triglyceride reduction: EPA and DHA reduce hepatic VLDL production. At 2-4g/day, triglycerides fall by 20-50%, one of the most evidence-backed supplement effects available.
  • →Mood and stress resilience: Omega-3 supplementation shows consistent benefits in mild-to-moderate depression (Mocking et al. 2016 meta-analysis) and blunts cortisol responses to psychological stress.

For context on how omega-3 status intersects with recovery and HRV, the Recovery Protocol covers the full picture of the autonomic nervous system and inflammatory recovery loop. For cardiovascular biomarker context, the Lab Work and Biomarkers Protocol addresses how omega-3 index fits alongside lipid panel markers like ApoB and triglycerides.

Why most people are chronically low

The modern Western diet is heavily skewed toward omega-6 fatty acids, primarily linoleic acid from vegetable oils (soybean, corn, sunflower, canola). The ratio of omega-6 to omega-3 in Western diets is estimated at 15:1 to 20:1. Ancestral and traditional diets are estimated at 4:1 or lower. EPA and DHA are not synthesized by the body from scratch: they must come from diet or the conversion of the plant-source precursor ALA (alpha-linolenic acid).

Common Misconception

Eating flaxseed, chia seeds, and walnuts does not adequately supply EPA and DHA. These foods contain ALA (alpha-linolenic acid), the plant-source omega-3 precursor. The conversion of ALA to EPA in humans is below 5-10%, and conversion from EPA to DHA is even lower, particularly in men. A tablespoon of flaxseed oil provides about 7g of ALA, which converts to less than 700mg of EPA and perhaps 200mg of DHA under ideal conditions. You cannot achieve an Omega-3 Index of 8% from plant sources alone without supplementation.

The practical sources that raise the Omega-3 Index effectively are fatty fish (salmon, sardines, mackerel, herring, anchovies) and EPA+DHA supplements from fish oil, krill oil, or algal oil. Algal oil is the preferred option for people who avoid fish: it is the original source of EPA and DHA in the food chain (fish accumulate omega-3s by eating algae), contains no fish-derived contaminants, and is environmentally sustainable. The clinical evidence for algal oil on Omega-3 Index elevation is comparable to fish oil.

How to reach an Omega-3 Index above 8%

The dose required to reach an Omega-3 Index above 8% depends on your starting point. From the typical American baseline of around 4-5%, reaching above 8% usually requires 2-3g/day of combined EPA+DHA. Supplementing 1g/day is often insufficient to achieve this target, which explains why many low-dose fish oil trials show modest effects.

Practical Sources and Their EPA+DHA Content

Wild salmon (3.5 oz)

1.5-2.5g EPA+DHA. 3-4 servings per week provides adequate omega-3 intake for most people to reach index above 8%.

Sardines (3.5 oz, canned)

1.5-2.0g EPA+DHA. One of the most sustainable, low-mercury options. Regular sardine intake is the cheapest path to omega-3 sufficiency.

Fish oil supplement (2g/day EPA+DHA)

Note: a 1g fish oil capsule typically contains only 300-600mg EPA+DHA. You need 4-8 standard capsules to reach 2g EPA+DHA unless using concentrated formulations (60-90% EPA+DHA).

Algal oil (vegan)

Available in 500-600mg EPA+DHA per capsule. Comparable Omega-3 Index elevation to fish oil in clinical trials. Preferred for those avoiding fish or fish-derived supplements.

Measure the index before supplementing, then retest 4 months later. Red blood cell turnover takes 3-4 months, so shorter retesting intervals underestimate the impact. If the index remains below 8% after 4 months of 2g/day EPA+DHA, increase to 3-4g/day and retest. Most people reach above 8% within 4-8 months of consistent supplementation at adequate doses.

Supplement Quality Warning

Fish oil oxidizes rapidly. Rancid fish oil provides no clinical benefit and may be harmful. Signs of oxidized fish oil: a strong fishy smell, fish-burp aftertaste, or a cloudy appearance. Purchase from brands that provide third-party IFOS (International Fish Oil Standards) certification, or use fresh algal oil formulations. Store in the refrigerator after opening. The best signal: quality fish oil from a reputable source should have minimal odor.

Frequently asked questions

My fish oil bottle says 1,000mg per capsule. Is that 1,000mg of EPA+DHA?

Almost certainly not. A standard 1,000mg fish oil softgel typically contains 300-600mg of EPA+DHA combined, with the remainder being other fats. To find the actual EPA+DHA dose, look at the Supplement Facts panel for the EPA and DHA listed in milligrams per serving. Many people take 1 capsule per day and get 300-400mg EPA+DHA, which is far below the 2-3g/day needed to move the Omega-3 Index meaningfully. Concentrated fish oil products (labeled as 60-80% omega-3 or "concentrated EPA/DHA") provide 600-900mg EPA+DHA per capsule and require fewer capsules per day.

Can I get enough omega-3s from flaxseed and walnuts if I don't eat fish?

Not to reach an Omega-3 Index above 8%. Plant-source omega-3s come as ALA, which converts to EPA at roughly 5-8% efficiency in humans and to DHA at far lower rates. To get 2g EPA+DHA from ALA conversion, you would need to consume 25-40g of ALA daily, which is physiologically impractical. Algal oil is the solution for people who avoid fish: it provides EPA and DHA directly (derived from algae, which is what fish eat), bypasses the conversion problem entirely, and achieves the same Omega-3 Index elevation as fish oil in clinical testing.

Does the Omega-3 Index matter if I'm already young and healthy?

Yes, for two reasons. First, the cardiovascular protection appears to accrue over decades of high omega-3 status, not just in older adults with established disease. Starting earlier gives more time for tissue incorporation and long-term benefit. Second, the non-cardiovascular effects, including muscle protein synthesis, HRV, cognitive function, and inflammatory resolution from training, are acutely relevant regardless of age. Young, active people benefit from high omega-3 status for recovery and performance, not just longevity.

What is the difference between EPA and DHA? Do I need both?

EPA and DHA have overlapping but distinct roles. EPA is more anti-inflammatory and anti-arrhythmic. DHA is the structural fatty acid for the brain and retina, about 30-40% of brain fatty acids by weight. Both are needed. Fish oil typically provides both. The REDUCE-IT trial used EPA alone and showed a large cardiovascular benefit; the STRENGTH trial used EPA+DHA and did not. The debate about EPA-only versus EPA+DHA for cardiovascular events is ongoing, but for general health optimization targeting the Omega-3 Index, combined EPA+DHA from fish oil or algal oil is appropriate. Most people are deficient in both.

How do I test my Omega-3 Index?

Several direct-to-consumer services offer finger-prick dried blood spot Omega-3 Index testing: OmegaQuant (the lab founded by William Harris, who developed the Omega-3 Index), Ulta Lab Tests, and some panels from Function Health and InsideTracker. The OmegaQuant Basic test is typically around $50 and includes EPA, DHA, and the computed index. Retest 4 months after any supplementation change, not sooner, since red blood cell turnover takes 3-4 months to fully reflect dietary changes.

What to Remember

  • →The Omega-3 Index measures EPA and DHA as a percentage of red blood cell fatty acids. It reflects the past 3-4 months of omega-3 status, not a single meal. Below 4% is high cardiovascular risk; above 8% is cardioprotective.
  • →Most Western adults have an Omega-3 Index of 4-6%. Reaching above 8% typically requires 2-3g/day of EPA+DHA combined, or 3-4 servings of fatty fish per week. Most standard fish oil capsules contain 300-600mg EPA+DHA, not 1,000mg, check the label.
  • →Plant-source omega-3s (ALA from flaxseed, chia, walnuts) cannot substitute for EPA and DHA. ALA converts to EPA at below 5-10% efficiency and to DHA at even lower rates. Algal oil provides EPA and DHA directly and is the correct solution for people avoiding fish.
  • →EPA and DHA reduce triglycerides by 20-50% at 2-4g/day, one of the most consistent and evidence-backed supplement effects available. They also reduce VLDL production, lower inflammation, and improve cardiac ion channel function (anti-arrhythmic).
  • →Beyond cardiovascular health, high omega-3 status improves muscle protein synthesis, supports HRV and autonomic function, reduces exercise-induced inflammation, and is associated with lower rates of depression and cognitive decline.
  • →Measure before supplementing, then retest after 4 months. Rancid fish oil provides no benefit: choose IFOS-certified brands or algal oil, store refrigerated, and check for a minimal odor (quality omega-3s should not smell strongly fishy).

Related on Protocol

ProtocolProtocol

Lab Work and Biomarkers Protocol

The full framework for interpreting blood markers: what to test, when, and what ranges actually mean for optimization versus disease prevention.

Read
LearnHealth

What Your Liver Enzymes Tell You

ALT, AST, and GGT explained: the patterns that distinguish NAFLD from alcoholic liver disease from muscle-source elevations.

Read
LearnHealth

How to Interpret Your Iron Panel

Ferritin, transferrin saturation, TIBC: what out-of-range values actually mean for energy, recovery, and long-term health.

Read

Track your biomarker trends over time

Protocol stores your Omega-3 Index, lipid panel, and inflammatory markers across panels, so you can see whether supplementation is actually moving your numbers and how they connect to your recovery and performance data.

Get started free

References

Key Researchers

  • William Harris (University of South Dakota / OmegaQuant) Developed the Omega-3 Index as a cardiovascular risk biomarker. Produced the foundational cohort analyses showing the 10-fold risk difference between below 4% and above 8%.
  • Philip Calder (University of Southampton) Immunomodulatory effects of EPA and DHA. Extensive work on omega-3s and inflammatory resolution, cytokine modulation, and clinical outcomes in metabolic disease.
  • Charles Serhan (Harvard Medical School) Discovery of resolvins, protectins, and maresins, the specialized pro-resolving mediators derived from EPA and DHA. Showed that omega-3s actively resolve inflammation rather than merely suppressing it.

Key Studies

  • Harris & Von Schacky (2004) Preventive Medicine. Proposed the Omega-3 Index (EPA+DHA as percentage of RBC fatty acids) as a cardiovascular risk factor. Pooled analysis showed 10-fold difference in sudden cardiac death risk between index below 4% and above 8%.
  • Yokoyama et al. (2007): JELIS Lancet. 18,645 Japanese patients with hypercholesterolemia. EPA supplementation at 1.8g/day reduced major coronary events by 19% in the secondary prevention group over 5 years.
  • Bhatt et al. (2019): REDUCE-IT NEJM. 8,179 statin-treated patients with elevated triglycerides. 4g/day icosapent ethyl reduced MACE by 25% over 4.9 years. Used EPA only, not EPA+DHA combination.
  • Smith et al. (2011) American Journal of Clinical Nutrition. 4g/day EPA+DHA supplementation increased muscle protein synthesis rate by 50% in response to amino acids plus insulin in older adults. Established omega-3 sensitization of the mTOR pathway.
  • Mocking et al. (2016) Translational Psychiatry. Meta-analysis of 13 randomized trials. EPA-enriched omega-3 supplementation produced significant benefit in major depressive disorder, with EPA-dominant formulations outperforming DHA-dominant.

Apps & Tools

  • OmegaQuant The lab founded by William Harris (who developed the Omega-3 Index). Finger-prick dried blood spot testing, roughly $50 for the Basic panel. The most direct way to measure your actual index rather than estimating from diet.
  • IFOS (International Fish Oil Standards) Third-party certification program for fish oil purity, potency, and freshness. Check whether your current supplement has IFOS certification before assuming quality.